The global cryogenic storage equipment market was valued at USD 7.8 billion in 2025 and is projected to expand to USD 13.2 billion by 2034, growing at a CAGR of 6.8%. That growth is being driven by a convergence of forces: the expansion of IVF treatment globally, the rapid build-out of biobanking infrastructure, the growth of the biologics pharmaceutical market, and the increasing recognition that cryogenic storage is not a passive infrastructure cost but an active clinical and research capability that requires systematic management.

This guide covers cryogenic technology, services, transport, storage dewars, and laboratory solutions as they apply to IVF clinics, fertility units, biobanks, and research institutions – the specifications that matter, the failure modes to understand, and the operational framework that turns a collection of equipment into a functioning cryogenic programme.

What is cryogenic technology and why does it define modern reproductive medicine?

Cryogenic technology is the science and engineering of producing, managing, and applying materials at temperatures below -150°C. In reproductive medicine and biological research, it means one thing above all: liquid nitrogen at -196°C and the infrastructure that keeps biological material at that temperature reliably, continuously, and safely.

The biological case for cryogenic technology is straightforward. At approximately -130°C, cellular metabolism stops. Enzymatic activity ceases. Ice crystal formation cannot occur. Biological material enters a preserved state in which degradation effectively does not happen. Liquid nitrogen at -196°C provides a 66°C safety margin below that critical threshold, accommodating the temperature perturbations that occur during access events, filling procedures, and transport without compromising sample integrity.

The market for cryogenic storage has evolved significantly, moving beyond simple vacuum-insulated vessels to include IoT-enabled monitoring, automated retrieval systems, and ultra-low nitrogen consumption technologies. The practical implications of these advances for IVF laboratories are considerable. Continuous remote monitoring transforms what was a manual checking procedure into a real-time data system. Automated retrieval reduces the temperature excursion associated with manual access. Ultra-low evaporation vessel designs extend supply buffers and reduce LN2 consumption costs.

Advances in cryogenic tech reshaping laboratory practice

The most clinically significant advance in cryogenic tech over the past decade has been the universal adoption of vitrification. The ultra-rapid cooling technique plunges embryos and oocytes into liquid nitrogen at rates fast enough to prevent ice crystal formation, producing the glassy amorphous state in which cellular structure is preserved intact. Post-thaw embryo survival rates in accredited laboratories using optimised vitrification protocols consistently reach 80 to 95 per cent.

Vapour phase storage technology has addressed the cross-contamination concern associated with liquid phase storage. By holding samples in the cold nitrogen vapour above the liquid surface, typically at -140°C to -190°C, vapour phase systems eliminate liquid-mediated contact between samples while maintaining temperatures well below -130°C. For regulated fertility programmes where sample provenance documentation is a regulatory obligation, the structural advantage of vapour phase storage is independent of the probability of actual cross-contamination events.

IoT integration is the most significant infrastructure development. Temperature and LN2 level sensors connected to cloud monitoring platforms allow laboratory managers to review storage conditions remotely, receive automated alarm notifications out of hours, and maintain continuous digital audit trails that support regulatory compliance documentation.

What makes an effective cryogenic solution

An effective cryogenic solution for long-term biological sample preservation is a system, not a product. The storage vessel, LN2 supply, monitoring infrastructure, consumables, safety controls, and documented procedures must all work together to maintain samples below -130°C reliably, with sufficient redundancy to protect against foreseeable failure modes.

The storage vessel selection drives most downstream decisions. Evaporation rate determines supply interval and safety buffer. Storage capacity must accommodate current volume with growth headroom. Phase configuration – liquid or vapour – affects cross-contamination risk management. Neck design governs the trade-off between LN2 loss and access ergonomics.

LN2 supply is the variable most frequently underplanned. The supply model must match consumption volume, with a minimum 14-day buffer for facilities storing active patient samples and a secondary emergency contingency that can be activated without advance notice. The global biologics market was valued at approximately USD 312 billion in 2025 and is expanding at 8.3% CAGR, driving proportional growth in cold chain infrastructure requirements.

Monitoring infrastructure converts passive storage into active management. A cryogenic solution without continuous monitoring and out-of-hours alarm capability relies entirely on scheduled manual checks – an approach that leaves a significant window of undetected risk between check times.

Cryogenic service: what every laboratory programme requires

A formal cryogenic service framework is the element most often absent from laboratory cryogenic programmes, and its absence is consistently identified in audit reviews. The framework must cover vessel inspection, supply management, safety equipment maintenance, and regulatory compliance documentation.

Daily pre-use vessel inspection is the operational foundation. Every storage dewar must be checked at the start of each working day for frost or condensation on the outer shell, which indicates vacuum failure, and for LN2 level against the previous day’s reading. Any vessel showing signs of vacuum compromise must be removed from service immediately. A written inspection log must be maintained for every vessel.

Pressurised cryogenic vessels require formal competent person inspection under the Pressure Systems Safety Regulations 2000, with a written scheme of examination specifying the inspection interval and inspector qualifications. Oxygen depletion monitoring equipment requires calibration and maintenance on a documented schedule. A sensor that is out of calibration or past its service interval provides no reliable protection at the critical 19.5 per cent oxygen threshold.

Cryogenic transport: safe sample movement between sites

Cryogenic transport presents a specific set of technical and regulatory challenges that differ materially from static storage. Within a facility, moving LN2-containing dewars requires purpose-designed trolleys or carts and formal manual handling risk assessment. Between facilities, cryopreserved biological samples must be transported in dry shippers – vessels in which liquid nitrogen is absorbed into a porous internal matrix, eliminating free liquid and enabling IATA-compliant air transport.

Dry shipper selection for cryogenic transport requires matching the holding time specification to the total transit time plus a meaningful safety margin for delays. An improperly charged dry shipper or one with insufficient holding time is the primary cause of sample loss during transport. Charging procedure must be followed precisely to ensure maximum LN2 absorption and minimum free liquid.

Cryogenic storage dewars: selection, performance and failure modes

The cryogenic storage dewar is the central piece of cryo equipment in any biological preservation programme. Its selection determines the baseline performance of the entire cryogenic solution.

Evaporation rate is the most operationally significant specification and the most consistently underweighted in procurement decisions. The difference between a vessel losing 0.1 litres of LN2 per day and one losing 0.4 litres per day accumulates to 109.5 litres annually and 547 litres over a five-year vessel lifetime. That difference in LN2 consumption cost frequently exceeds the price premium between vessel tiers.

Vacuum integrity is the parameter that determines whether a dewar continues to perform to specification throughout its service life. Frost or condensation on the outer shell and an abnormally high evaporation rate are the definitive indicators of vacuum failure. Either sign requires immediate removal from service, content transfer to a serviceable vessel, and quarantine pending competent person inspection.

Dewar wall failure occurs through several mechanisms: mechanical impact that cracks or deforms the inner vessel or compromises the vacuum seal; corrosion of internal components that introduces outgassing; and age-related seal degradation that eventually affects all vacuum-insulated vessels. Understanding these failure modes supports both preventive inspection practice and end-of-life replacement planning.

Cryogenic tanks represent the largest product segment with approximately 38.5% market share in 2025, anticipated to grow at 6.9% CAGR through 2034, reaching approximately USD 5.08 billion.

Cryo storage industries: who uses cryogenic storage and why

Cryo storage serves a broader range of industries than most laboratory professionals encounter directly. IVF and fertility medicine, biobanking, pharmaceutical biologics development, veterinary reproductive medicine, stem cell research, and hospital research departments all maintain active cryogenic storage programmes with broadly similar technical requirements and meaningfully different regulatory frameworks.

The common requirement across all of these sectors is the same: maintain temperature below -130°C continuously, with adequate supply buffer, monitoring, and documented procedures. The International Society for Biological and Environmental Repositories reports approximately 800 biobanks operating worldwide, with many undertaking significant infrastructure investments to maintain cryogenic storage capabilities. The biobanking sector’s growth, driven by precision medicine, personalised therapeutics development, and clinical trial infrastructure, is one of the primary growth drivers for the cryogenic storage equipment market globally.

How Cryolab supports cryogenic laboratory and clinical programmes worldwide

Cryolab has supplied cryogenic technology, storage vessels, dry shippers, vitrification consumables, cryogenic canes and sleeves, safety equipment, and laboratory consumables to IVF clinics, fertility units, sperm banks, biobanks, and research institutions for over 40 years. ISO 9001:2015 certified and based in Chichester, Cryolab works directly with embryologists, laboratory managers, and procurement professionals to specify cryogenic solutions suited to the programme, facility, and regulatory requirements of each customer.

Use CryoGPT, Cryolab’s AI assistant for cryogenic and IVF laboratory questions, contact the Cryolab team directly, or browse the full storage vessel range.